Prediction of the response to chemotherapy in acute leukemia by a short-term test in vitro

J. D. Schwarzmeier, Elisabeth M. Paietta, K. Mittermayer, R. Pirker

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

To detect sensitivity or resistance of leukemic cells to chemotherapy prior to treatment, a short-term incubation method was employed. Blast cells from the peripheral blood or bone marrow of adult patients presenting with different forms of acute leukemia were analyzed for in vitro responsiveness to anticancer drugs in terms of suppression of 3H-uridine incorporation into cellular nucleic acids. The following agents were tested over a wide range of concentrations: Adriamycin, cytosine arabinoside, thioguanine, 6-mercaptopurine, prednisone, and 4-hydroperoxycyclophosphamide. Retrospectively, the in vitro data were compared to the clinical response of the patients to polychemotherapy. In the majority of the patients, in vitro cytotoxic effectiveness of Adriamycin (doxorubicin) and cytosine arabinoside reflected the in vivo situation. The levels of in vitro inhibition that could distinguish between drug-sensitive and drug-resistant diseases appeared to be 30% for Adriamycin and 20% for cytosine arabinoside. No correlation was found between the Adriamycin effect in vitro and the proliferative state (rate of 3H-thymidine incorporation) of the leukemic cell population. Serial in vitro sensitivity testing during the course of disease of various patients proved the ability of the test system to detect acquired resistance to chemotherapeutic agents. Therefore, the assay might serve as a reliable tool in the selection of effective chemotherapy in individual patients suffering from acute leukemia.

Original languageEnglish (US)
Pages (from-to)390-395
Number of pages6
JournalCancer
Volume53
Issue number3
StatePublished - 1984
Externally publishedYes

Fingerprint

Leukemia
Doxorubicin
Drug Therapy
Cytarabine
perfosfamide
Pharmaceutical Preparations
Thioguanine
6-Mercaptopurine
Uridine
Prednisone
Combination Drug Therapy
Thymidine
Nucleic Acids
In Vitro Techniques
Blood Cells
Bone Marrow
Population
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Schwarzmeier, J. D., Paietta, E. M., Mittermayer, K., & Pirker, R. (1984). Prediction of the response to chemotherapy in acute leukemia by a short-term test in vitro. Cancer, 53(3), 390-395.

Prediction of the response to chemotherapy in acute leukemia by a short-term test in vitro. / Schwarzmeier, J. D.; Paietta, Elisabeth M.; Mittermayer, K.; Pirker, R.

In: Cancer, Vol. 53, No. 3, 1984, p. 390-395.

Research output: Contribution to journalArticle

Schwarzmeier, JD, Paietta, EM, Mittermayer, K & Pirker, R 1984, 'Prediction of the response to chemotherapy in acute leukemia by a short-term test in vitro', Cancer, vol. 53, no. 3, pp. 390-395.
Schwarzmeier, J. D. ; Paietta, Elisabeth M. ; Mittermayer, K. ; Pirker, R. / Prediction of the response to chemotherapy in acute leukemia by a short-term test in vitro. In: Cancer. 1984 ; Vol. 53, No. 3. pp. 390-395.
@article{ba7180383fd94e74b59d8bc2cf90c3f2,
title = "Prediction of the response to chemotherapy in acute leukemia by a short-term test in vitro",
abstract = "To detect sensitivity or resistance of leukemic cells to chemotherapy prior to treatment, a short-term incubation method was employed. Blast cells from the peripheral blood or bone marrow of adult patients presenting with different forms of acute leukemia were analyzed for in vitro responsiveness to anticancer drugs in terms of suppression of 3H-uridine incorporation into cellular nucleic acids. The following agents were tested over a wide range of concentrations: Adriamycin, cytosine arabinoside, thioguanine, 6-mercaptopurine, prednisone, and 4-hydroperoxycyclophosphamide. Retrospectively, the in vitro data were compared to the clinical response of the patients to polychemotherapy. In the majority of the patients, in vitro cytotoxic effectiveness of Adriamycin (doxorubicin) and cytosine arabinoside reflected the in vivo situation. The levels of in vitro inhibition that could distinguish between drug-sensitive and drug-resistant diseases appeared to be 30{\%} for Adriamycin and 20{\%} for cytosine arabinoside. No correlation was found between the Adriamycin effect in vitro and the proliferative state (rate of 3H-thymidine incorporation) of the leukemic cell population. Serial in vitro sensitivity testing during the course of disease of various patients proved the ability of the test system to detect acquired resistance to chemotherapeutic agents. Therefore, the assay might serve as a reliable tool in the selection of effective chemotherapy in individual patients suffering from acute leukemia.",
author = "Schwarzmeier, {J. D.} and Paietta, {Elisabeth M.} and K. Mittermayer and R. Pirker",
year = "1984",
language = "English (US)",
volume = "53",
pages = "390--395",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Prediction of the response to chemotherapy in acute leukemia by a short-term test in vitro

AU - Schwarzmeier, J. D.

AU - Paietta, Elisabeth M.

AU - Mittermayer, K.

AU - Pirker, R.

PY - 1984

Y1 - 1984

N2 - To detect sensitivity or resistance of leukemic cells to chemotherapy prior to treatment, a short-term incubation method was employed. Blast cells from the peripheral blood or bone marrow of adult patients presenting with different forms of acute leukemia were analyzed for in vitro responsiveness to anticancer drugs in terms of suppression of 3H-uridine incorporation into cellular nucleic acids. The following agents were tested over a wide range of concentrations: Adriamycin, cytosine arabinoside, thioguanine, 6-mercaptopurine, prednisone, and 4-hydroperoxycyclophosphamide. Retrospectively, the in vitro data were compared to the clinical response of the patients to polychemotherapy. In the majority of the patients, in vitro cytotoxic effectiveness of Adriamycin (doxorubicin) and cytosine arabinoside reflected the in vivo situation. The levels of in vitro inhibition that could distinguish between drug-sensitive and drug-resistant diseases appeared to be 30% for Adriamycin and 20% for cytosine arabinoside. No correlation was found between the Adriamycin effect in vitro and the proliferative state (rate of 3H-thymidine incorporation) of the leukemic cell population. Serial in vitro sensitivity testing during the course of disease of various patients proved the ability of the test system to detect acquired resistance to chemotherapeutic agents. Therefore, the assay might serve as a reliable tool in the selection of effective chemotherapy in individual patients suffering from acute leukemia.

AB - To detect sensitivity or resistance of leukemic cells to chemotherapy prior to treatment, a short-term incubation method was employed. Blast cells from the peripheral blood or bone marrow of adult patients presenting with different forms of acute leukemia were analyzed for in vitro responsiveness to anticancer drugs in terms of suppression of 3H-uridine incorporation into cellular nucleic acids. The following agents were tested over a wide range of concentrations: Adriamycin, cytosine arabinoside, thioguanine, 6-mercaptopurine, prednisone, and 4-hydroperoxycyclophosphamide. Retrospectively, the in vitro data were compared to the clinical response of the patients to polychemotherapy. In the majority of the patients, in vitro cytotoxic effectiveness of Adriamycin (doxorubicin) and cytosine arabinoside reflected the in vivo situation. The levels of in vitro inhibition that could distinguish between drug-sensitive and drug-resistant diseases appeared to be 30% for Adriamycin and 20% for cytosine arabinoside. No correlation was found between the Adriamycin effect in vitro and the proliferative state (rate of 3H-thymidine incorporation) of the leukemic cell population. Serial in vitro sensitivity testing during the course of disease of various patients proved the ability of the test system to detect acquired resistance to chemotherapeutic agents. Therefore, the assay might serve as a reliable tool in the selection of effective chemotherapy in individual patients suffering from acute leukemia.

UR - http://www.scopus.com/inward/record.url?scp=0021365430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021365430&partnerID=8YFLogxK

M3 - Article

VL - 53

SP - 390

EP - 395

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -